On June 5, 2024, Marinus Pharmaceuticals, Inc. was sued for violations of the federal securities laws in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased or otherwise
acquired publicly traded Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.